Recombinant immunotoxins

Breast Cancer Res Treat. 1996;38(1):3-9. doi: 10.1007/BF01803778.

Abstract

Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.

Publication types

  • Review

MeSH terms

  • ADP Ribose Transferases*
  • Antibodies, Monoclonal / therapeutic use
  • Bacterial Toxins*
  • Breast Neoplasms / therapy*
  • Exotoxins / therapeutic use
  • Female
  • Humans
  • Immunotoxins / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Virulence Factors*

Substances

  • Antibodies, Monoclonal
  • Bacterial Toxins
  • Exotoxins
  • Immunotoxins
  • Recombinant Proteins
  • Virulence Factors
  • ADP Ribose Transferases
  • toxA protein, Pseudomonas aeruginosa